Aggressive treatment of dyslipidemia: a review of supporting evidence.
Clinical trial data are now sufficient to support aggressive treatment of dyslipidemia. Cholesterol-lowering therapy is known to reduce the risk of clinical events across a wide range of lipid levels, even in patients with "normal" levels. Current data support lowering low-density lipoprotein cholesterol (LDL-C) levels at least to those recommended by the National Cholesterol Education Program, but perhaps even more aggressively in some patients. Of the available cholesterol-lowering agents, statins produce the greatest reductions in LDL-C levels and coronary events and are currently the best treatment option for most patients.
Stein
E A
EA
Medical Research Laboratories, Highland Heights, Kentucky 41076, USA. esteinmrl@aol.com. esteinmrl@aol.com
D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000503:physiopathology; D006801:Humans; D006903:Hydroxymethylglutaryl CoA Reductases / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy*; D012307:Risk Factors
D008078:Cholesterol, LDL; D006903:Hydroxymethylglutaryl CoA Reductases